VTYX
NASDAQVentyx Biosciences Inc.
Ventyx Biosciences Inc. (VTYX) is a Biotechnology: Pharmaceutical Preparations company listed on NASDAQ. There were no new wire items for VTYX in the last 30 days. The most recent was published Mar 16, 2026.
Latest news
25 items- SECSEC Form 15-12G filed by Ventyx Biosciences Inc.15-12G - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form EFFECT filed by Ventyx Biosciences Inc.EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form EFFECT filed by Ventyx Biosciences Inc.EFFECT - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Ventyx Biosciences Inc.SCHEDULE 13D/A - Ventyx Biosciences, Inc. (0001851194) (Subject)
- INSIDERSenior VP, Finance Gonzales Roy returned 5,313 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERDirector Subramaniam Somu returned 3,337,495 shares to the company (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERSEC Form 4 filed by Director White William Richard4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Moore Matthew Richard4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERSEC Form 4 filed by Director Cadoret-Manier Onaiza4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERSEC Form 4 filed by Director Hulme Allison4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERDirector Gujrathi Sheila returned 130,000 shares to the company (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERCHIEF SCIENTIFIC OFFICER Nuss John returned 489,481 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERCEO AND PRESIDENT Mohan Raju returned 2,372,863 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- INSIDERChief Medical Officer Forman Mark S returned 6,000 shares to the company, closing all direct ownership in the company (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- SECSEC Form S-8 POS filed by Ventyx Biosciences Inc.S-8 POS - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form S-8 POS filed by Ventyx Biosciences Inc.S-8 POS - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form S-8 POS filed by Ventyx Biosciences Inc.S-8 POS - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form S-8 POS filed by Ventyx Biosciences Inc.S-8 POS - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form POS AM filed by Ventyx Biosciences Inc.POS AM - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form POS AM filed by Ventyx Biosciences Inc.POS AM - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form 25-NSE filed by Ventyx Biosciences Inc.25-NSE - Ventyx Biosciences, Inc. (0001851194) (Subject)
- SECVentyx Biosciences Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)
- SECSEC Form 8-K filed by Ventyx Biosciences Inc.8-K - Ventyx Biosciences, Inc. (0001851194) (Filer)
- INSIDERDirector Subramaniam Somu disposed of 694,718 shares (SEC Form 4)4 - Ventyx Biosciences, Inc. (0001851194) (Issuer)
- SECSEC Form DEFA14A filed by Ventyx Biosciences Inc.DEFA14A - Ventyx Biosciences, Inc. (0001851194) (Filer)
VTYX FAQ
8 questionsWhat does Ventyx Biosciences Inc. do?
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops small molecule product candidates for inflammatory diseases and autoimmune disorders. The company's lead product candidate is VTX958, a tyrosine kinase type 2 inhibitor that is in phase I clinical trials for the treatment of immune-mediated diseases, such as psoriasis, inflammatory bowel disease, psoriatic arthritis, and lupus. It also develops VTX002, an oral sphingosine 1 phosphate receptor 1 modulator that has completed phase I clinical trials for the treatment of ulcerative colitis; and VTX2735, a...What is the latest news on VTYX?
Quantisnow has not tracked any new filings, ratings or press releases for VTYX in the last 30 days. The most recent wire item was published on March 16, 2026.Where does VTYX stock trade?
Ventyx Biosciences Inc. (VTYX) is listed on NASDAQ.What sector and industry is VTYX in?
Ventyx Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Ventyx Biosciences Inc. go public?
Ventyx Biosciences Inc. (VTYX) completed its IPO in 2021.What are analysts saying about VTYX?
Across the last 8 analyst actions on Ventyx Biosciences Inc., there were 3 upgrades and 5 downgrades. The most recent action was from H.C. Wainwright: Buy with a $18.00 price target on 2025-11-05. Recent price targets range from $6.00 to $18.00.What companies are similar to VTYX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare VTYX side-by-side with any of them on Quantisnow.How can I track VTYX on Quantisnow?
Quantisnow aggregates Ventyx Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VTYX to receive live email and push alerts on every new disclosure.